Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Akela total consolidated revenues increase to $7.3M for six months ended June 30, 2011

Akela Pharma, Inc. and PharmaForm, a leading specialty contract service provider in the area of pharmaceutical dosage form development and manufacturing, today announced its financial results for the three and six months and year ended June 30, 2011.

16 Aug 2011

NAI reaches settlement with VPX over beta-alanine patent litigation

Natural Alternatives International, Inc., a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced that it reached a settlement with one of the defendants to litigation pending before the U.S. District Court for the District of Delaware, Vital Pharmaceutical, Inc..

12 Aug 2011

Thorne acquires global rights to Q-Cell, an advanced formulation Coenzyme Q10

Thorne Research, Inc., a leader in developing and manufacturing pure, high quality nutritional supplements marketed through licensed healthcare practitioners, has acquired exclusive global rights to market Q-Cell, an advanced formulation Coenzyme Q10 (CoQ10) supplement formerly marketed under the brand name Q-Best.

12 Aug 2011

Advaxis completes ADXS-PSA prostate cancer construct pre-IND meeting with the FDA

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has completed a pre-IND (Investigational New Drug) meeting with the FDA on August 10 to discuss the development plan for ADXS-PSA, a construct for the treatment of prostate cancer.

12 Aug 2011

Single engineered protein blocks two related angiogenic receptors

Cancer needs blood. In fact, some cancer medications work solely to slow or prevent cancer cells from creating new capillaries, choking off their much-needed blood and nutrient supply to halt the growth of tumors.

12 Aug 2011

Researchers develop epidermal electronic system

Through a combination of careful theoretical modeling and precise micro-manufacturing, a team of engineers and scientists has developed a new type of ultra-thin, self-adhesive electronics device that can effectively measure data about the human heart, brain waves and muscle activity - all without the use of bulky equipment, conductive fluids, or glues.

12 Aug 2011

China Pharma second quarter revenue increases 18% to $19.6 million

China Pharma Holdings, Inc., a specialty pharmaceuticals company in China, today announced financial results for the quarter ended June 30, 2011.

11 Aug 2011

InVivo Therapeutics reports net loss of $1,370,000 for second quarter 2011

InVivo Therapeutics Holdings Corp., a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today reported financial results for the three and six months ended June 30, 2011 and provided a business update.

11 Aug 2011

Study finds higher free iron content in dark beer

A team of researchers from the University of Valladolid has analysed 40 brands of beer, discovering that dark beer has more free iron than pale and non-alcoholic beers. Iron is essential to the human diet, but also helps oxidise the organic compounds that give these beverages stability and flavour.

11 Aug 2011

Althea hosts Health and Wellness Fair for employees

Althea Technologies, Inc., a leading provider of development and manufacturing services for biotechnology and pharmaceutical companies, held its inaugural Health and Wellness Fair today.

11 Aug 2011

FDA approves Gilead's Complera for treatment of HIV-1 infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Complera, a complete single-tablet regimen for the treatment of HIV-1 infection in treatment-naïve adults.

11 Aug 2011

Once daily HIV ‘combo’ drug approved in U.S.

The U.S. Food and Drug Administration (FDA) has given its approval to a once daily HIV treatment that combines Gilead Sciences Inc.'s drug Truvada with Johnson & Johnson's drug Edurant, Gilead said Wednesday.

11 Aug 2011

NCI, Genesis Biopharma sign CRADA agreement to develop cancer immunotherapies

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer immunotherapies, today announced it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute.

10 Aug 2011

Protox reports net loss of $3.2 million for second quarter 2011

Protox Therapeutics Inc., a developer of innovative products for the treatment of urological diseases, today announced financial results and achievements for the quarter ended June 30, 2011.

10 Aug 2011

Akela announces new corporate focus on PharmaForm

Akela Pharma, Inc. today announced a new strategic focus on its profitable pharmaceutical contract manufacturing business, PharmaForm, LLC.

9 Aug 2011

Simcere second quarter total revenue increases 0.3% to US$84.4 million

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported preliminary unaudited financial results for the quarter ended June 30, 2011.

9 Aug 2011

Exactech's new Optetrak Logic knee implant effective for painful arthritis

Kevin Hindle, a 47-year-old manufacturing engineer at Exactech, Inc., a global orthopaedic device company, regained his active lifestyle with an innovative new knee implant that he helped develop.

9 Aug 2011

Gilead to acquire Genentech's OCP facility, other process development assets

Gilead Sciences, Inc. today announced that the company has signed a definitive agreement under which Gilead will purchase a clinical biologics manufacturing facility and certain process development assets located in Oceanside, California from Genentech, a member of the Roche Group.

9 Aug 2011

K-V sells assets of Nesher to Zydus and Zynesher Pharmaceuticals

K-V Pharmaceutical Company today announced the completion and closing of the previously announced sale of assets of Nesher Pharmaceuticals, Inc., the Company's wholly-owned generic subsidiary, and the Company's generic business and assets to Zydus Pharmaceuticals (USA), Inc and Zynesher Pharmaceuticals (USA) LLC.

9 Aug 2011